Comprehensive SDSU/UCSD Cancer Center Partnership 1 of 2

全面的 SDSU/UCSD 癌症中心合作伙伴关系 1 of 2

• 批准号: 8899089
• 负责人: Elva M Arredondo
• 金额: $ 22.06万
• 依托单位: SAN DIEGO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-29 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8899089
• 关键词: Antigens; Biochemistry; Biological Availability; Biotechnology; Cancer Center; Cancer Vaccines; Communities; Community Health Education; Community Outreach; Dendritic Cells; Development; Drug Formulations; Encapsulated; Faculty; Immune response; Immunotherapy; Knowledge; Malignant neoplasm of prostate; Mannose; Minority; Peptide Vaccines; Peptides; Pilot Projects; Proteins; Research; Scientist; Students; System; Training; Vaccines; anticancer research; base; clinical application; mannose receptor; medically underserved; nanoparticle; novel vaccines; outreach program; programs; survivin

DESCRIPTION (provided by applicant): Significant advances in biotechnology and biochemistry have led to the discovery of a large number of cancer vaccines based on peptides and proteins. However, the development of suitable and efficient carrier systems remains a major challenge since the vaccine bioavailability is limited by enzymatic degradation. We developed recently several promising new vaccines for prostate cancer based on natural and modified survivin-derived peptides. We propose to encapsulate the survivin-derived peptide vaccines into our newly developed nanoparticles targeted to the mannose receptors on the dendritic cells. The inclusion of mannose or some of its derivatives in the nanoparticle formulation is expected to enhance delivery of active antigen and is the major conceptual advance of this pilot project. We suggest that this novel vaccine will induce potent and specific immune responses against prostate cancer. Because survivin is highly expressed in all prostate cancer, this new nanoparticle-vaccine strategy may have important clinical applications. This approach may provide a potential avenue for immunotherapy of prostate cancer, as many other prostate cancer-associated antigens have been described to date.

描述（由申请人提供）：生物技术和生物化学的重大进步导致大量基于肽和蛋白质的癌症疫苗的发现。然而，由于疫苗生物利用度受到酶降解的限制，开发合适且有效的载体系统仍然是一个重大挑战。我们最近开发了几种基于天然和修饰的存活蛋白衍生肽的有前景的前列腺癌新疫苗。我们建议将生存素衍生的肽疫苗封装到我们新开发的针对树突状细胞上的甘露糖受体的纳米颗粒中。在纳米颗粒制剂中加入甘露糖或其一些衍生物预计将增强活性抗原的递送，这是该试点项目的主要概念进展。我们认为这种新型疫苗将诱导针对前列腺癌的有效且特异性的免疫反应。由于生存素在所有前列腺癌中都高度表达，因此这种新的纳米颗粒疫苗策略可能具有重要的临床应用。这种方法可能为前列腺癌的免疫治疗提供潜在的途径，因为迄今为止已经描述了许多其他前列腺癌相关抗原。